- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 331
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
- Interventions
- oblimersen sodium, rituximab, ifosfamide, carboplatin, etoposide, filgrastim, pegfilgrastim, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Gastric Adenocarcinoma
- Interventions
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- Procedure
- Lead sponsor
- Banner Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Gilbert, Arizona
- Conditions
- Impulsive Aggression Comorbid With ADHD in Children
- Interventions
- Molindone
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Los Angeles, California • Santa Ana, California + 25 more
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Interventions
- Lithium, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 4
- States / cities
- Miami, Florida • Belmont, Massachusetts • New York, New York + 1 more
- Conditions
- Melanoma
- Interventions
- Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Smoking Cessation
- Interventions
- Aggressive Therapy
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Staten Island, New York
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Interventions
- Romidepsin, Gemcitabine, Oxaliplatin, Dexamethasone, Pegfilgrastim
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • St Louis, Missouri
- Conditions
- Prosthetic Joint Infection
- Interventions
- VT-X7 Treatment System with Tobramycin Sulfate, Standard of Care, Two-stage exchange arthroplasty, VT-X7 Treatment System with Vancomycin Hydrochloride
- Combination Product · Drug · Procedure
- Lead sponsor
- Osteal Therapeutics, Inc.
- Industry
- Eligibility
- 22 Years to 84 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Torrance, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Child Development Disorders, Pervasive
- Interventions
- Parent Training, Psychoeducational Program
- Behavioral · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 3 Years to 7 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 48
- States / cities
- San Francisco, California • Bloomington, Illinois • Canton, Illinois + 26 more
- Conditions
- Neoplasms
- Interventions
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
- Conditions
- Anger Problems, Aggression
- Interventions
- Countering Chronic Anger and Aggression Related to Trauma and Transgressions (CART)
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Fort Cavazos, Texas
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
- Combination Product · Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 26
- States / cities
- Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 23 more
- Conditions
- Prosthetic-joint Infection
- Interventions
- VT-X7 Treatment System, Two-stage exchange arthroplasty, SOC Antibiotics, Experimental Antibiotics
- Combination Product · Procedure · Drug
- Lead sponsor
- Osteal Therapeutics, Inc.
- Industry
- Eligibility
- 22 Years to 84 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sarasota, Florida + 15 more
- Conditions
- Borderline Personality Disorder
- Interventions
- guanfacine (Tenex)
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
- Interventions
- Parent Management Training, Placebo, Intuniv
- Behavioral · Other · Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- T-Cell Lymphoma, B-Cell Lymphoma
- Interventions
- enzastaurin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Duarte, California • Chicago, Illinois • New York, New York + 4 more
- Conditions
- Agitation, Alzheimer's Disease
- Interventions
- AVP-923-20, Placebo, AVP-923-30
- Drug
- Lead sponsor
- Avanir Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
- Conditions
- Metabolic Syndrome
- Interventions
- Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
- Drug · Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 19 Years to 79 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Interventions
- Vincristine Sulfate Liposome Injection plus rituximab
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia